Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

Rituxan Hycela (rituximab/hyaluronidase) - Biogen, Roche

Jaypirca (pirtobrutinib) - Eli Lilly

betamethasone microsphere (DE-102) - Santen

doxorubicin hydrochloride - Generic mfg.

vincristine - Generic mfg.

prednisone delayed-release tablet - Generic mfg.

cyclophosphamide - Generic mfg.

Mabtas (rituximab biosimilar) - Intas

Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov) - Oct 14, 2026 - P3 | N=102 | Recruiting | Sponsor: SWOG Cancer Research Network | Not yet recruiting ➔ Recruiting
Enrollment open • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma

http://clinicaltrials.gov/ct2/show/NCT07220187

Oct 14, 2026